Pierre-Emmanuel Brachet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pierre-Emmanuel Brachet has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Leconte
Clinical Research Department, Centre Francois Baclesse, Caen, France
4 shared publications - Bénédicte Clarisse
Clinical Research Department, Centre Francois Baclesse, Caen, France
4 shared publications - Justine Lequesne
Clinical Research, Centre François Baclesse, 14000 Caen, France
4 shared publications - Florence Joly
Medical Oncology Department, Centre Francois Baclesse, Caen, France
3 shared publications - Dinu Stefan
Radiation Oncology, Centre François Baclesse, 3 Avenue du Général Harris, 14000 Caen, France
2 shared publications - Joëlle Lacroix
Radiology Department, CLCC François Baclesse, 14000 Caen, France
2 shared publications
Latest Publications
- Open Access
- 31 October 2025
- Published by Springer Nature in Research Square
Impact of androgen receptor pathway inhibitors on cognitive function in elderly patients treated for metastatic prostate cancer
Androgen receptor pathway inhibitors (ARPI) are commonly used in addition to androgen deprivation therapy (ADT) for metastatic prostate cancer (mPC). However, there is limited data on their cognitive impact in elderly patients. This prospective multicenter trial recruited castration-resistant mPC patients aged ≥70 receiving ADT+ARPI, patients receiving ADT alone, and healthy controls (HC). Cognition was assessed with a self-report questionnaire (subjective cognition) and cognitive tests addressing six domains: processing speed/attention, working memory, verbal memory, visual memory, visuospatial abilities, and executive functions (objective cognition). At baseline (before starting ARPI for ADT+ARPI patients), objective cognitive impairment concerned 36 (51%), 5 (26%) and 3 (10%) ADT+ARPI patients, ADT patients and HC, respectively. After 3 and 6 months of follow-up, adjusted scores showed poorer subjective cognition in ADT+ARPI patients than in ADT patients (p≤0.033). ADT+ARPI patients also had lower objective performance in processing speed/attention domain at all visits (p≤0.010). Although limited by small sample sizes, our study shows for the first time that ARPI+ADT can increase the risk of impacting objective and subjective cognition in elderly mPC patients, compared to ADT alone.
- 31 October 2025
- Published by Springer Nature in Research Square
Open AccessImpact of androgen receptor pathway inhibitors on cognitive function in elderly patients treated for metastatic prostate cancer
Androgen receptor pathway inhibitors (ARPI) are commonly used in addition to androgen deprivation therapy (ADT) for metastatic prostate cancer (mPC). However, there is limited data on their cognitive impact in elderly patients. This prospective multicenter trial recruited castration-resistant mPC patients aged ≥70 receiving ADT+ARPI, patients receiving ADT alone, and healthy controls (HC). Cognition was assessed with a self-report questionnaire (subjective cognition) and cognitive tests addressing six domains: processing speed/attention, working memory, verbal memory, visual memory, visuospatial abilities, and executive functions (objective cognition). At baseline (before starting ARPI for ADT+ARPI patients), objective cognitive impairment concerned 36 (51%), 5 (26%) and 3 (10%) ADT+ARPI patients, ADT patients and HC, respectively. After 3 and 6 months of follow-up, adjusted scores showed poorer subjective cognition in ADT+ARPI patients than in ADT patients (p≤0.033). ADT+ARPI patients also had lower objective performance in processing speed/attention domain at all visits (p≤0.010). Although limited by small sample sizes, our study shows for the first time that ARPI+ADT can increase the risk of impacting objective and subjective cognition in elderly mPC patients, compared to ADT alone.
- 2 February 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 165 (1) , 30-39
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study
- 2 February 2022
- Published by Elsevier in Gynecologic Oncology
- Vol. 165 (1) , 30-39
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study
- Open Access
- 22 February 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial
Background: Brain metastases often occur in cancer evolution. They are not only responsible for death but also for disorders affecting the quality of life and the cognitive functions. Management of brain metastases usually consists in multi-modality treatments, including neurosurgery, whole brain radiotherapy (WBRT), and more recently radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT), systemic treatment (chemotherapy or targeted therapy), combined or not with corticosteroids. Almost 20% of brain metastases can present recent (within 15 days) bleeding signs on neuro-imagery. In these conditions, WBRT is the usual treatment. Yet, patients may benefit from a more aggressive strategy with SRT or FSRT. However, these options were suspected to possibly major the risk of brain haemorrhage, although no scientifically proven. Radiation oncologists therefore usually remain reluctant to deliver SRS/FSRT for bleeding brain metastases. It is therefore challenging to establish a standard of care for the treatment of bleeding brain metastases. We propose a phase II trial to simultaneously assess safety and efficacy of FSRT to manage brain metastases with hemorrhagic signal. Methods: The STEREO-HBM study is a multicenter two-step non-randomised phase II trial addressing patients with at least one bleeding brain metastasis out of a maximum of 3 brain metastases. Each brain metastasis will be treated with 30 Gy in 3 fractions for 1 week. The main endpoint is based on both safety and efficacy endpoints as proposed by Bryant and Day’s design. Safety endpoint is defined as the rate of bleeding complications 4 months post-FSRT while efficacy endpoint is defined as the 6-month local control rate. Multi-modal MRI will be used to assess intra-tumoral hemorrhagic events before and after treatment. Patients’ quality of life will also be assessed. Discussion: Management of bleeding brain metastases is still debated and poorly explored in clinical trials. There is sparse and weak data on the signification of pretreatment intra-tumour haemorrhagic signs or on the risk of brain bleeding complications after FSRT. We expect this first prospective phase 2 trial in this particular setting will allow to clarify the place of FSRT to optimally manage bleeding brain metastases. Trial registration: NCT 03696680, registered October, 4, 2018. Protocol version: Version 2.1 dated from 2018/11/09.
- 22 February 2020
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-9
Open AccessStereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial
Background: Brain metastases often occur in cancer evolution. They are not only responsible for death but also for disorders affecting the quality of life and the cognitive functions. Management of brain metastases usually consists in multi-modality treatments, including neurosurgery, whole brain radiotherapy (WBRT), and more recently radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT), systemic treatment (chemotherapy or targeted therapy), combined or not with corticosteroids. Almost 20% of brain metastases can present recent (within 15 days) bleeding signs on neuro-imagery. In these conditions, WBRT is the usual treatment. Yet, patients may benefit from a more aggressive strategy with SRT or FSRT. However, these options were suspected to possibly major the risk of brain haemorrhage, although no scientifically proven. Radiation oncologists therefore usually remain reluctant to deliver SRS/FSRT for bleeding brain metastases. It is therefore challenging to establish a standard of care for the treatment of bleeding brain metastases. We propose a phase II trial to simultaneously assess safety and efficacy of FSRT to manage brain metastases with hemorrhagic signal. Methods: The STEREO-HBM study is a multicenter two-step non-randomised phase II trial addressing patients with at least one bleeding brain metastasis out of a maximum of 3 brain metastases. Each brain metastasis will be treated with 30 Gy in 3 fractions for 1 week. The main endpoint is based on both safety and efficacy endpoints as proposed by Bryant and Day’s design. Safety endpoint is defined as the rate of bleeding complications 4 months post-FSRT while efficacy endpoint is defined as the 6-month local control rate. Multi-modal MRI will be used to assess intra-tumoral hemorrhagic events before and after treatment. Patients’ quality of life will also be assessed. Discussion: Management of bleeding brain metastases is still debated and poorly explored in clinical trials. There is sparse and weak data on the signification of pretreatment intra-tumour haemorrhagic signs or on the risk of brain bleeding complications after FSRT. We expect this first prospective phase 2 trial in this particular setting will allow to clarify the place of FSRT to optimally manage bleeding brain metastases. Trial registration: NCT 03696680, registered October, 4, 2018. Protocol version: Version 2.1 dated from 2018/11/09.
- Open Access
- 4 March 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 198
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radiosensitizer is crucial to improve the patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be considered as a promising class of radiosensitizer. The aim of this study is to evaluate Olaparib, a PARPi, as radiosensitizing agent, combined with the Stupp protocol, namely temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) in first line treatment of partially or non-resected GBM. The OLA-TMZ-RTE-01 study is a multicenter non-randomized phase I/IIa trial including unresectable or partially resectable GBM patients, from 18 to 70 years old. A two-step dose-escalation phase I design will first determine the recommended phase 2 dose (RP2D) of olaparib, delivered concomitantly with TMZ plus conventional irradiation for 6 weeks and as single agent for 4 weeks (radiotherapy period), and second, the RP2D of olaparib combined with adjuvant TMZ (maintenance period). Phase IIa will assess the 18-month overall survival (OS) of this combination. In both phase I and IIa separately considered, the progression-free survival, the objective response rate, the neurocognitive functions of patients, emotional disorders among caregivers, the survival without toxicity, degradation nor progression, the complications onset and the morphologic and functional MRI (magnetic resonance imaging) parameters will be also assessed as secondary objectives. Ancillary objectives will explore alteration of the DNA repair pathways on biopsy tumor, proton magnetic resonance spectroscopy parameters to differentiate tumor relapse and radionecrosis, and an expanded cognition evaluation. Up to 79 patients will be enrolled: 30 patients in the phase I and 49 patients in the phase IIa. Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. Ancillary studies will help to identify genetic biomarkers predictive of PARPi efficacy as radiosensitizer. NCT03212742 , registered June, 7, 2017. Protocol version: Version 2.2 dated from 2017/08/18.
- 4 March 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 198
Open AccessPhase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol
Despite multimodality treatments including neurosurgery, radiotherapy and chemotherapy, glioblastoma (GBM) prognosis remains poor. GBM is classically considered as a radioresistant tumor, because of its high local recurrence rate, inside the irradiation field. The development of new radiosensitizer is crucial to improve the patient outcomes. Pre-clinical data showed that Poly (ADP-ribose) polymerase inhibitors (PARPi) could be considered as a promising class of radiosensitizer. The aim of this study is to evaluate Olaparib, a PARPi, as radiosensitizing agent, combined with the Stupp protocol, namely temozolomide (TMZ) and intensity modulated radiotherapy (IMRT) in first line treatment of partially or non-resected GBM. The OLA-TMZ-RTE-01 study is a multicenter non-randomized phase I/IIa trial including unresectable or partially resectable GBM patients, from 18 to 70 years old. A two-step dose-escalation phase I design will first determine the recommended phase 2 dose (RP2D) of olaparib, delivered concomitantly with TMZ plus conventional irradiation for 6 weeks and as single agent for 4 weeks (radiotherapy period), and second, the RP2D of olaparib combined with adjuvant TMZ (maintenance period). Phase IIa will assess the 18-month overall survival (OS) of this combination. In both phase I and IIa separately considered, the progression-free survival, the objective response rate, the neurocognitive functions of patients, emotional disorders among caregivers, the survival without toxicity, degradation nor progression, the complications onset and the morphologic and functional MRI (magnetic resonance imaging) parameters will be also assessed as secondary objectives. Ancillary objectives will explore alteration of the DNA repair pathways on biopsy tumor, proton magnetic resonance spectroscopy parameters to differentiate tumor relapse and radionecrosis, and an expanded cognition evaluation. Up to 79 patients will be enrolled: 30 patients in the phase I and 49 patients in the phase IIa. Combining PARP inhibitors, such as olaparib, with radiotherapy and chemotherapy in GBM may improve survival outcomes, while sparing healthy tissue and preserving neurocognitive function, given the replication-dependent efficacy of olaparib, and the increased PARP expression in GBM as compared to non-neoplastic brain tissue. Ancillary studies will help to identify genetic biomarkers predictive of PARPi efficacy as radiosensitizer. NCT03212742 , registered June, 7, 2017. Protocol version: Version 2.2 dated from 2017/08/18.
- 1 December 2015
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 9 (4) , 209-213
Progrès en biologie moléculaire et thérapies ciblées : enjeux psychiques
Les progrès en biologie moléculaire et les traitements par thérapies ciblées ont révolutionné la prise en charge des cancers. Ces traitements diffèrent des chimiothérapies cytotoxiques classiques en agissant sur une ou plusieurs cibles moléculaires impliquées dans l’oncogenèse. Ces molécules ont des effets secondaires spécifiques, dont certains peuvent agir sur les fonctions thymiques. Certaines thérapies ciblées, comme les antiangiogéniques oraux, engendrent souvent un état de fatigue profond et peuvent avoir un effet direct sur le psychisme en affectant la cognition et la mémoire. Des effets secondaires d’ordre psychiatrique ont aussi été rapportés mais restent anecdotiques. Délivrées souvent sous forme orale, ces thérapies modifient l’implication et l’autonomie du patient dans son traitement ainsi que la représentation qu’il a de sa maladie et peuvent avoir un retentissement psychique indirect. De même, ces traitements sont donnés sur de longues périodes, et la gestion chronique des effets secondaires comme les troubles digestifs et cutanés devient rapidement difficile sur le plan psychologique. Pour un nombre croissant de ces nouvelles thérapies, l’indication de traitement est fondée sur la recherche d’une anomalie moléculaire qui ne sera retrouvée que pour un nombre restreint de patients induisant souvent des espoirs déçus de la part des patients. De manière contemporaine aux progrès de la biologie moléculaire, les thérapies ciblant des mutations constitutionnelles impliquent de nouvelles problématiques entrecroisant oncogénétique, nécessité thérapeutique et contraintes techniques. Ainsi, dans ce contexte scientifique nouveau, le patient est souvent déstabilisé par un parcours de plus en plus complexe de sa prise en charge.
- 1 December 2015
- Published by PiscoMed Publishing Pte. Ltd. in Psycho-Oncologie
- Vol. 9 (4) , 209-213
Progrès en biologie moléculaire et thérapies ciblées : enjeux psychiques
Les progrès en biologie moléculaire et les traitements par thérapies ciblées ont révolutionné la prise en charge des cancers. Ces traitements diffèrent des chimiothérapies cytotoxiques classiques en agissant sur une ou plusieurs cibles moléculaires impliquées dans l’oncogenèse. Ces molécules ont des effets secondaires spécifiques, dont certains peuvent agir sur les fonctions thymiques. Certaines thérapies ciblées, comme les antiangiogéniques oraux, engendrent souvent un état de fatigue profond et peuvent avoir un effet direct sur le psychisme en affectant la cognition et la mémoire. Des effets secondaires d’ordre psychiatrique ont aussi été rapportés mais restent anecdotiques. Délivrées souvent sous forme orale, ces thérapies modifient l’implication et l’autonomie du patient dans son traitement ainsi que la représentation qu’il a de sa maladie et peuvent avoir un retentissement psychique indirect. De même, ces traitements sont donnés sur de longues périodes, et la gestion chronique des effets secondaires comme les troubles digestifs et cutanés devient rapidement difficile sur le plan psychologique. Pour un nombre croissant de ces nouvelles thérapies, l’indication de traitement est fondée sur la recherche d’une anomalie moléculaire qui ne sera retrouvée que pour un nombre restreint de patients induisant souvent des espoirs déçus de la part des patients. De manière contemporaine aux progrès de la biologie moléculaire, les thérapies ciblant des mutations constitutionnelles impliquent de nouvelles problématiques entrecroisant oncogénétique, nécessité thérapeutique et contraintes techniques. Ainsi, dans ce contexte scientifique nouveau, le patient est souvent déstabilisé par un parcours de plus en plus complexe de sa prise en charge.